Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE-LUNG: Chemo-escalation for Osimertinib in EGFRm NSCLC
NCT05281406Phase 2Recruiting
- Sponsor
- Goethe University Frankfurt
- Start
- Nov 2021
- Primary completion
- Nov 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed, cisplatin and carboplatin in non-small cell lung cancer (NSCLC), sponsored by Goethe University Frankfurt. Primary endpoint: Progression Free Survival at 2 years. Started Nov 2021; status: recruiting.
02
Drugs
pemetrexedcisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05281406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281406.